REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
15/06/2026
Voltar para busca
Dado oficial do USPTO
QI LU
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
16/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
27/12/2019
Data de registro
15/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/06/2021
Última transação
16/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
KON, ELISSA GARBER
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized polygon shape with curved cutouts on its sides and down its middle, to the left of two Chinese characters which are above the stylized wording "QI LU".
Titulares e representantes
Titulares
QILU PHARMACEUTICAL CO., LTD.
Representantes
Dana Stewart-Mekdara Global Trademarks, Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for the prevention and treatment of cancernervous system diseasescardio-cerebrovascular diseasepsychiatric disordersophthalmic diseasesandrology diseasesall for human purposes; Pharmaceutical preparations for the prevention and treatment of cancernervous system diseasescardio-cerebrovascular diseasepsychiatric disordersophthalmic diseasesandrology diseasesall for human purposes; Drugs for medical purposes for the prevention and treatment of cancernervous system diseasescardio-cerebrovascular diseasepsychiatric disordersophthalmic diseasesandrology diseasesall for human purposes; Ointments for pharmaceutical purposes for the prevention and treatment of cancernervous system diseasescardio-cerebrovascular diseasepsychiatric disordersophthalmic diseasesandrology diseasesall for human purposes; Crude drugsextracts of hops for pharmaceutical purposeseucalyptus for pharmaceutical purposesMint for pharmaceutical purposesMalt for pharmaceutical purposesPepsins for pharmaceutical purposesThymol for pharmaceutical purposesTurpentine for pharmaceutical purposesFlaxseed for pharmaceutical purposesFerments for pharmaceutical purposesCytostatics for pharmaceutical purposesBalms for pharmaceutical purposesDigestives for pharmaceutical purposesIodine for pharmaceutical purposesAlcohol for pharmaceutical purposesStarch for pharmaceutical purposesall for the prevention and treatment of cancernervous system diseasescardio-cerebrovascular diseasepsychiatric disordersophthalmic diseasesandrology diseasesall for human purposes; Cultures of microorganisms for medical or veterinary use; Nutritive substances for microorganisms for medical purposes; Veterinary preparations for pigfarm animalscompanion animalspetsruminantsvaccineanti-parasiteantipyreticanalgesicanti-inflammatoryantibioticdisinfectants and feed additive preparations; Medicines for veterinary purposes for pigfarm animalscompanion animalspetsruminantsvaccineanti-parasiteantipyreticanalgesicanti-inflammatoryantibioticdisinfectants and feed additive preparations; antibiotics
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/10/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
30/09/2021
FIMP
FINAL DISPOSITION PROCESSED
29/09/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
15/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/03/2021
PUBO
PUBLISHED FOR OPPOSITION
30/03/2021
GPNX
NOTIFICATION PROCESSED BY IB
28/03/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/03/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
22/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
22/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/02/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
17/02/2021
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
16/02/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/02/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/02/2021
ALIE
ASSIGNED TO LIE
01/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/10/2020
RFNT
REFUSAL PROCESSED BY IB
15/05/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/04/2020
RFRR
REFUSAL PROCESSED BY MPU
28/04/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/04/2020
CNRT
NON-FINAL ACTION WRITTEN
09/04/2020
MAFR
APPLICATION FILING RECEIPT MAILED
07/04/2020
DOCK
ASSIGNED TO EXAMINER
03/04/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/04/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/04/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QI LU ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.